Menu
Enrolling by invitation NCT06699654

"Comparison of Spirulina Gels for Treating Stage II Grade B Periodontitis"

No phase Interventional Periodontitis Stage II

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Placebo gel, Spirulina Gel, Spirulina Nanoparticles Gel.
Who it may be relevant to
Registry conditions: Periodontitis Stage II. Basic parameters: No limits · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Egypt
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

Comparative Study Between Spirulina Gel and Spirulina Nanoparticles Gel for Treatment of Stage II Grade B Periodontitis: Randomized Control Clinical Study with Radiological and Biochemical Assessment

Overview

This randomized controlled clinical study investigates the effectiveness of Spirulina gel and Spirulina nanoparticles gel in treating Stage II Grade B periodontitis. The research aims to compare the two formulations in terms of clinical, radiological, and biochemical outcomes, such as pocket depth reduction, alveolar bone density improvement, and inflammatory marker levels. The study seeks to provide insights into the potential of Spirulina-based therapies for enhancing periodontal health.

Interventions

  • Other Placebo gel
    A gel without active Spirulina components applied as a control intervention.
  • Dietary supplement Spirulina Gel
    A conventional Spirulina gel formulation applied as a periodontal therapy.
  • Dietary supplement Spirulina Nanoparticles Gel
    A novel Spirulina nanoparticles gel formulation applied as a periodontal therapy.

Primary outcome measures

  • Reduction in Probing Pocket Depth (PPD) [Time frame: at baseline, 1 month , 3 months, 6 months]
Secondary outcome measures (2)
  • Radiographic Bone Density Improvement [Time frame: at baseline and after 6 months]
  • Biochemical Marker Levels [Time frame: Measured at baseline, 1 month ,3 months, and 6 months]

Eligibility criteria

Inclusion criteria

  • Patients with good systemic health.
  • Patients who can maintain good oral hygiene.
  • Attachment loss 3-4 mm and probing pocket depth ≤ 5mm. Exclusion criteria for this study include: ·
  • Any systemic disease that affects the periodontium. ·
  • Pregnant, postmenopausal women. ·
  • People who take anti-inflammatory drugs, antibiotics, or vitamins within the previous 3 month.
  • People who use mouth washes regularly ·
  • Participation in other clinical trials.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Double blind
Primary purpose
Treatment

Study locations

Egypt · 1 center
  • Doctor Mohamed Samir Periodontal and Implantology Clinic — El-Sheikh Zayed City

Identifiers

NCT: NCT06699654 · KFSIRB200-68

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗